Market capitalization | €927.15m |
Enterprise Value | €828.63m |
P/E (TTM) P/E ratio | 31.37 |
EV/FCF (TTM) EV/FCF | 25.54 |
EV/Sales (TTM) EV/Sales | 6.98 |
P/S ratio (TTM) P/S ratio | 7.81 |
P/B ratio (TTM) P/B ratio | 6.48 |
Dividend yield | 1.80% |
Last dividend (FY23) | €0.59 |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
Sep '24 |
+/-
%
|
||
Revenue | 119 119 |
6%
6%
|
|
Gross Profit | 87 87 |
6%
6%
|
|
EBITDA | 42 42 |
6%
6%
|
EBIT (Operating Income) EBIT | 36 36 |
5%
5%
|
Net Profit | 30 30 |
24%
24%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BioGaia AB engages in the development, marketing, and sale of probiotic products. It operates through the following segments: Pediatrics, Adult Health, and Other. The Pediatrics segment sells drops, oral rehydration solutions, digestive health tablets, and also royalties pertaining to pediatric products. The Adult Health segment include gut health tablets, oral health products, and offers cultures as an ingredient in a licensee's dairy product. The Other segment consists royalties from the development projects, and revenue from packaging solutions. The company was founded by Jan Annwall and Peter Michael Rothschild in 1990 and is headquartered in Stockholm, Sweden.
Head office | Sweden |
CEO | Theresa Agnew |
Employees | 210 |
Founded | 1990 |
Website | www.biogaia.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.